Abstract
The contributions of cytochrome P450 3A (CYP3A) and P-glycoprotein to sirolimus oral bioavailability in rats were evaluated by coadministration of sirolimus (Rapamune) with the CYP3A inhibitor ketoconazole or the P-glycoprotein inhibitord-α-tocopheryl poly(ethylene glycol 1000) succinate (TPGS). Groups of six male Sprague-Dawley rats (250–300 g) were administered Rapamune (1 mg/kg) by oral gavage, alone and with ketoconazole (30 mg/kg) or TPGS (50 mg/kg). Sirolimus levels were measured in whole blood over a 6-h time course. SirolimusCmax (6.6 ± 1.6 versus 26 ± 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC0–6) (22 ± 7 versus 105 ± 27 ng · h/ml) were increased 3- to 5-fold by ketoconazole. MedianTmax (1.5–2 h) was unchanged. TPGS had no effect on sirolimus absorption. The interaction of sirolimus with P-glycoprotein was also evaluated in vitro using HCT-8 and Caco-2 cell monolayers. Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC50 of 0.625 to 1.25 μM (cyclosporine caused >80% inhibition at 5 μM). Sirolimus did not demonstrate significant polarized flux in either direction using the same monolayers (basolateral-to-apical flux was <2 times the apical-to-basolateral). Moreover, sirolimus flux was not impacted by cyclosporine, suggesting that it does not undergo P-glycoprotein-mediated transport in this system. The lack of significant sirolimus transport by P-glycoprotein may, in part, explain the lack of a TPGS effect on sirolimus absorption in rats.
Footnotes
-
↵1 Current address: Sunesis Corporation, 341 Oyster Point Boulevard, South San Francisco, CA 94080.
-
This work was funded by Avlan Pharmaceuticals Ltd. (Flatts, Smith, Bermuda), a joint venture of AvMax Inc. and Elan Pharmaceutical Technologies.
-
DOI: 10.1124/jpet.102.036541
- Abbreviations:
- CYP3A
- cytochrome P450 3A
- P-gp
- P-glycoprotein
- MRP
- multidrug resistance-related protein
- TPGS
- d-α-tocopheryl poly(ethylene glycol 1000) succinate
- HPLC-MS
- high-pressure liquid chromatography-mass spectroscopy
- QC
- quality control
- AUC
- area under the concentration versus time curve
- P450
- cytochrome P450
- R123
- rhodamine 123
- M1–3
- unidentified sirolimus metabolites
- TBS
- Tween-phosphate-buffered saline
- 39-ODM
- 39-O-desmethylsirolimus
- CDNB
- 1-chloro-2,4-dinitrobenzene
- Received March 25, 2002.
- Accepted June 21, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|